diabetes%20insipidus
DIABETES INSIPIDUS
Diabetes insipidus is a polyuric disease characterized by excretion of a large volume of hypotonic urine and hypernatremia. It is due to the absence of antidiuretic hormone.
Central (hypothalamic or neurohypophyseal) diabetes insipidus is the inability to secrete & produce vasopressin in the neurohypophyseal system. It is due to damage to the pituitary gland & hypothalamus, may be due to diseases, head injuries, neurosurgery, infection or genetic or autoimmune disorders.
In nephrogenic diabetes insipidus, there is inappropriate renal response to vasopressin. Kidney function may be impaired by drugs & by chronic disorders like polycystic kidney disease, sickle cell disease, kidney failure, partial ureteral block, hypokalemia, hypocalcemia, low protein diet & genetic disorders.
Primary polydipsia have abnormal increase in fluid intake.
Drug Information

Indication: HTN for patients in whom combination therapy is appropriate. Reduce the risk of stroke in patients w/ HTN &...

Indication: HTN for patients in whom combination therapy is appropriate. Reduce the risk of stroke in patients w/ HTN &...

Indication: Essential HTN when BP is inadequately controlled by monotherapy w/ telmisartan.

Indication: 2nd-line therapy in the treatment of HTN in patients whose BP is not adequately controlled by monotherapy.

Exforge HCT
amlodipine + hydrochlorothiazide + valsartan

Indication: Essential HTN.

Indication: Mild to moderate HTN.

Indication: HTN. Reduce risk of stroke in patient w/ HTN & left ventricular hypertrophy.

Indication: Essential HTN in patients whose BP is inadequately controlled by olmesartan medoxomil or hydrochlorothiazide a...

Indication: Epilepsy (except absence & myoclonic seizures). Acute mania. Maintenance for bipolar affective disorders t...

Indication: HTN. Reduce risk of stroke in patients w/ HTN & left ventricular hypertrophy.

1  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.